POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biol ...
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.336
https://www.valueinhealthjournal.com/article/S1098-3015(21)02131-8/fulltext
Title :
POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biol ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02131-8&doi=10.1016/j.jval.2021.11.336
First page :
Section Title :
Open access? :
No
Section Order :
11112